Project Research Center for Clinical Trial and Preventive Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Nutrition. 2013 Jul-Aug;29(7-8):1030-6. doi: 10.1016/j.nut.2013.02.008.
The aim of this study was to evaluate the combined effects of 5-aminolevulinic acid phosphate (ALA-P) and iron on the glycemic index in mildly hyperglycemic adults.
This double-blind, randomized placebo-controlled trial comprised 212 subjects (ages 35-70 y, fasting plasma glucose 105-125 mg/dL or hemoglobin (Hb)A1c 6.1%-7.1%). These participants were randomly assigned to four groups receiving either one of three doses of ALA-P and iron as sodium ferrous citrate (5 mg and 0.6 mg, 5 mg and 1.8 mg, or 15 mg and 1.8 mg, respectively) or a placebo, administered orally once a day over a 12-wk period.
Fifteen mg ALA-P plus 1.8 mg iron decreased the fasting plasma glucose level (2.32 mg/dL, 95% confidence interval [CI], 0.24-4.42, P = 0.029), serum glycoalbumin (0.22%, 95% CI, 0.02-0.42; P = 0.031), and 2h-oral glucose tolerance test levels (14.2 mg/dL, 95% CI, 1.8-26.6; P = 0.025) more than the placebo. However, the levels of HbA1c, fasting insulin, serum 1,5-anhydro-d-glucitol, and Homeostasis Model of Assessment-Insulin Resistance showed no appreciable changes. The participant numbers with impaired glucose tolerance and impaired fasting glucose decreased in the highest dosage group of ALA-P plus iron compared with the placebo group.
An oral intake of ALA would be a novel approach to prevent type 2 diabetes mellitus.
本研究旨在评估 5-氨基乙酰丙酸磷酸盐（ALA-P）和铁联合应用对轻度高血糖成年人血糖指数的影响。
这是一项双盲、随机、安慰剂对照试验，纳入 212 名（年龄 35-70 岁，空腹血糖 105-125mg/dL 或糖化血红蛋白（Hb）A1c 6.1%-7.1%）参与者。这些参与者被随机分配到四组，分别接受三种剂量的 ALA-P 和铁作为柠檬酸亚铁（5mg 和 0.6mg、5mg 和 1.8mg 或 15mg 和 1.8mg）或安慰剂，每天口服一次，持续 12 周。
15mg ALA-P 加 1.8mg 铁可降低空腹血糖水平（2.32mg/dL，95%置信区间[CI]，0.24-4.42，P=0.029）、血清糖基化白蛋白（0.22%，95%CI，0.02-0.42；P=0.031）和 2 小时口服葡萄糖耐量试验水平（14.2mg/dL，95%CI，1.8-26.6；P=0.025），比安慰剂更显著。然而，HbA1c、空腹胰岛素、血清 1,5-脱水-d-葡萄糖醇和稳态模型评估的胰岛素抵抗水平没有明显变化。与安慰剂组相比，ALA-P 加铁的最高剂量组中糖耐量受损和空腹血糖受损的参与者数量减少。
口服 ALA 可能是预防 2 型糖尿病的一种新方法。
